The correct way to take Teclistamab-cqyv

Teritusumab(Teclistamab-cqyv) is a bispecificT cell engaging antibody that has received widespread attention in recent years. It is mainly used to treat multiple myeloma, especially in relapsed or refractory patients who have failed to respond to multiple other treatment options. This drug represents an important breakthrough in immune-targeted therapy. Its working mechanism is to simultaneously combine CD3+ T cells with myeloma cells expressing BCMA (B cell maturation antigen), activating the patient's own T cells to directly kill cancer cells. Therefore, the correct usage method is particularly critical to exert the effect of the drug and ensure the safety of the drug.

Unlike traditional oral or intravenous injection, teritolumab is administered by subcutaneous injection and is operated by professional medical personnel in a clinical setting. The advantage of this approach is that it reduces the risk of allergic reactions associated with intravenous infusion, while the drug is released more gently and is better tolerated. The initial stage of medication requires a dose escalation scheme, that is, gradually starting from smaller doses to reduce the incidence of immune-related adverse reactions such as cytokine release syndrome (CRS). Typically, initial treatment will be under observation in the hospital so that potential adverse effects can be dealt with promptly.

The entire treatment cycle is usually administered weekly until disease progression or unacceptable adverse effects. Before and after administration, patients need to undergo close monitoring, including evaluation of liver and kidney function, blood pictures, infection indicators, etc., to ensure that the metabolism and detoxification functions of the drug in the body are normal. At the same time, due to the strong immune activation, doctors may temporarily adjust the dose or extend the dosing interval based on the patient's physical response.

It is important to note that teritusumab is not a self-administered medication at home, and it is not recommended that patients inject it themselves or change the frequency of dosing without permission. Any dosage adjustment must be evaluated and decided by a specialist. Especially when symptoms such as fever, headache, hypotension, fatigue and other symptoms occur in the early stages of treatment, it is more necessary to seek medical attention promptly to evaluate whether it is related to CRS or other immune side effects.

Reference materials:https://www.tecvayli.com/